ABBV
NYSE · Biotechnology
Abbvie Inc
$265.21
+0.73 (+0.28%)
ABBV News30 articles
PGA Tour Finalizes 2028 Two-Tier Structure, 90 Cards Define New Era
PGA Tour finalizes 2028 two-tier system: 90 cards retained, 20 promotions. New structure aims to boost media value, with $3B investment from Strategic Sports Group.
AbbVie Completes $10.9B Apogee Buyout, Earnings Lift Delayed to 2032
AbbVie finalizes its $10.9B Apogee Therapeutics deal, with earnings accretion not expected until 2032. The acquisition tests investor patience as immunology sales fuel the wait.
AbbVie Completes $10.9B Apogee Buyout, Accretion Delayed to 2032
AbbVie closes its $10.9B Apogee acquisition, projecting EPS dilution until 2032, while strong Skyrizi and Rinvoq growth funds the long-term bet.
Pfizer Stock Hits 52-Week High at 10x Forward Earnings
Pfizer shares climbed 1.7% to $29.04, hitting a 52-week high, as the stock trades at 10x projected 2026 earnings, with a 5.9% dividend yield.
XLV Retreats from Record as Mid-Sized Health Care Names Lag
XLV hit a record $169.71 before closing lower, lagging the S&P 500 by 0.74 points. Weakness among smaller health care holdings offset gains in top components.
AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?
AstraZeneca and Bristol Myers Squibb are reportedly in merger talks, which could create a $455 billion pharmaceutical giant. Reuters has not confirmed the report.
Pfizer Stock Dips 1.9% but Dividend Adjusts Decline
Pfizer ended Friday at $24.54, down 1.9% unadjusted, but dividend-adjusted returns fell just 0.16%. The FDA's priority review for Talzenna offers a key catalyst for Q4.
Pfizer Gains 3.6% as Dividend Yield Attracts Income Investors
Pfizer (PFE) shares climbed 3.6% as its 6.9% dividend yield attracted income-focused investors, despite unchanged analyst estimates and a slight earnings forecast cut.
Eli Lilly Shares Gain on Atai Deal with $1 Billion Milestone Potential
Eli Lilly shares edged up 1.08% on a $3.8B deal with Atai Life Sciences, which could unlock up to $1 billion in milestone payments for psychedelic depression drugs.
Pfizer's Dividend Sustainability in Focus After HSBC Downgrade
Pfizer shares slid after HSBC downgraded the stock, turning investor attention to the sustainability of its 7.3% dividend yield amid a payout ratio near 60% of adjusted EPS guidance.
Lilly's GLP-1 Dominance Drives Near-Record Close, But Healthcare Rally Broadens
Eli Lilly closed near a record as XLV gained 2.65%, but other healthcare stocks like Johnson & Johnson and AbbVie drove more of the ETF's rise. Attention now turns to Lilly's $50 Medicare obesity drug offer and generic tirzepatide filings.
AbbVie Surges $17.8 Billion in Market Cap, Surpassing Apogee Deal Value
AbbVie shares soared 3.99% to $261.07, adding $17.8B in market value—more than the $10.9B Apogee deal. The stock now trades above analyst targets, setting up a key Q2 earnings report.
Pfizer Gains as 7% Yield Attracts, China Trial Scrutiny Looms
Pfizer (PFE) shares climbed 2.1% on Thursday, supported by a high dividend yield, but a U.S. House committee probe into its China trial data adds uncertainty.
AbbVie's $65B Surge Outpaces Apogee Acquisition Cost by Sixfold
AbbVie's stock surge added $65B in market cap, six times its $10.9B Apogee deal cost, as Skyrizi approval and immunology demand offset Humira declines.
AbbVie surges $18B in value ahead of Skyrizi pediatric approval
AbbVie shares soared 4.2% to a 52-week high, adding $18 billion in market value, surpassing the $10.9 billion Apogee acquisition price. FDA approval for pediatric Skyrizi use came after the close.
Alphabet's AI Cost Fears Trigger Nasdaq Slide; Dow Gains on Oil Drop
Alphabet (GOOGL) tumbled 5.5% on AI spending worries, pulling the Nasdaq down 1.41%, while a drop in oil prices lifted the Dow 0.12%.
AbbVie Acquires Apogee Therapeutics for $10.9B in Cash, Bolstering Pipeline
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding a promising eczema treatment to its pipeline as it seeks to offset declining Humira sales.
S&P 500 Edges Up, Nasdaq Slips as Micron Surge Offsets Tech Weakness
The S&P 500 and Dow edged higher, but the Nasdaq slipped as Micron's nearly 5% gain lifted chip stocks, while rising yields weighed on mega-cap tech.
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
Apogee Therapeutics stock jumped 47% after AbbVie agreed to buy the company for $135.11 per share in cash, adding late-stage eczema drug zumilokibart.
AbbVie to Buy Apogee in $10.9B Deal to Boost Immunology Pipeline
AbbVie acquires Apogee Therapeutics for $10.9 billion, paying a 49.49% premium for experimental eczema drug zumilokibart, as it seeks to bolster its immunology franchise.
AbbVie Nears $10.9B Apogee Takeover, Healthcare Stocks in Focus
AbbVie is reportedly close to acquiring Apogee Therapeutics for $10.9 billion in cash, offering a roughly 60% premium. A deal could be announced Monday, putting healthcare stocks in the spotlight.
Abivax shares drop despite positive Phase 3 results for ulcerative colitis drug
Abivax shares plunged 33.7% after hours despite obefazimod achieving clinical remission in over 50% of patients in a Phase 3 trial. The company plans to submit an FDA application in late Q4 2026.
Amazon Stock Climbs on AI Shopping Assistant Rollout via AWS
Amazon shares gained over 2% following the launch of AI shopping assistants for retailers through AWS, positioning the company as a neutral AI infrastructure provider.
AbbVie Stock Gains on Positive Pipeline Updates Ahead of Holiday
AbbVie closed Friday at $215.70, up 0.56%, after receiving a positive EU panel recommendation for MAVIRET in acute hepatitis C and releasing new oncology data ahead of ASCO.
Oruka Therapeutics Soars on Psoriasis Drug Data, Announces $500M Offering
Oruka Therapeutics shares surged after interim data showed its psoriasis drug ORKA-001 achieved 63.5% complete skin clearance. The company also announced a $500M public offering.
J&J Q1 Earnings Surpass Expectations, Lifts 2026 Forecast
Johnson & Johnson exceeded Wall Street's first-quarter forecasts, driven by strong performance from Darzalex and Tremfya. The company raised its full-year 2026 sales guidance.
SCHD ETF Sees Strong Q1 Inflows After Dividend Hike and Portfolio Overhaul
The Schwab U.S. Dividend Equity ETF (SCHD) reported a 3.3% dividend increase and $4 billion in first-quarter inflows following a significant portfolio reshuffle that boosted healthcare and tech exposure while reducing energy holdings.
Eli Lilly Inks $2.75B AI Drug Deal, Posts Positive Trial Data
Eli Lilly has entered a licensing deal with Insilico Medicine potentially worth $2.75 billion and reported strong late-stage clinical results for its immunology and obesity drugs.
Merck's $6.7B Terns Buyout Anchors Stock Near Offer Price
Merck has agreed to acquire Terns Pharmaceuticals in a $6.7 billion all-cash deal. Terns shares traded at $52.86, close to Merck's $53-per-share offer, as investors weigh the deal's completion.
AbbVie's Early Obesity Drug Trial Shows Promising Weight Loss Results
AbbVie reported its amylin-based obesity candidate ABBV-295 led to significant weight reduction in an early study, with no serious safety issues observed. The data marks a strategic step for the company as it seeks growth beyond immunology.